Linezolid:: pharmacokinetic characteristics and clinical studies

被引:39
作者
Bouza, E [1 ]
Muñoz, P [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Clin Microbiol & Infect Dis Dept, Madrid 28007, Spain
关键词
D O I
10.1046/j.1469-0691.2001.00061.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Linezolid is an oxazolidinone indicated in the treatment of nosocomial and community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections and vancomycin-resistant Enterococcus infections. The drug is also approved for use in complicated skin infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus, concurrent bacteremia associated with vancomycin-resistant Enterococcus faecium and concurrent bacteremia associated with community-acquired pneumonia caused by penicillin-susceptible Streptococcus pneumoniae.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 42 条
[1]   Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (Linezolid):: New treatment options for infections due to resistant organisms [J].
Antony, SJ ;
Bitter, KM ;
Moreland, T ;
Raudales, F ;
Diaz-Luna, H .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (05) :1341-1342
[2]   Therapy for Pneumococcal Infection at the Millennium: Doubts and Certainties [J].
Ball, Peter .
AMERICAN JOURNAL OF MEDICINE, 1999, 107 (01) :77-85
[3]   Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity [J].
Barbachyn, MR ;
Hutchinson, DK ;
Brickner, SJ ;
Cynamon, MH ;
Kilburn, JO ;
Klemens, SP ;
Glickman, SE ;
Grega, KC ;
Hendges, SK ;
Toops, DS ;
Ford, CW ;
Zurenko, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :680-685
[4]  
Barrett J F, 2000, Curr Opin Investig Drugs, V1, P181
[5]  
BIRMINGHAM MC, 2000, 40 INT C ANT AG CHEM, P488
[6]  
Brier ME, 1998, J INVEST MED, V46, p276A
[7]  
CAMMARATA SK, 2000, 40 INT C ANT AG CHEM
[8]  
CAMMARATA SK, 2001, AM J RESP CRIT CAR S, V161, pA654
[9]  
Cammarata SK, 2000, EUR RESPIR J, V16, p139S
[10]  
Cammarata SK, 2000, CLIN MICROBIOL INFEC, V6, P136